Mitogen-activated protein kinase kinase

Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a dual-specificity kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

Mitogen-activated protein kinase kinase
Identifiers
EC no.2.7.12.2
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Search
PMCarticles
PubMedarticles
NCBIproteins

MAP2K is classified as EC 2.7.12.2.

There are seven genes:

The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]

Role in melanoma

edit

MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

See also

edit

References

edit
  1. ^ Dérijard B, et al. (1995). "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms". Science. 267 (5198): 682–5. Bibcode:1995Sci...267..682D. doi:10.1126/science.7839144. PMID 7839144. S2CID 9153074.
  2. ^ Dwivedi, Gaurav; Kemp, Melissa L. (February 15, 2012). "Systemic Redox Regulation of Cellular Information Processing". Antioxidants & Redox Signaling. 16 (4): 374–80. doi:10.1089/ars.2011.4034. PMC 3279717. PMID 21939387.
  3. ^ Falchook, Gerald S.; Lewis, Karl D.; Infante, Jeffrey R.; Gordon, Michael S.; Vogelzang, Nicholas J.; DeMarini, Douglas J.; Fecher, Leslie A.; et al. (2012). "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial". The Lancet Oncology. 13 (8): 782–789. doi:10.1016/S1470-2045(12)70269-3. PMC 4109286. PMID 22805292.
edit